ORYZON Appoints Greg Weaver as Global Chief Financial Officer
PR Newswire - Mon Jan 12, 2:00AM CST
Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, today announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015. Weaver brings more than 30 years of experience to Oryzon, including extensive financial and operational experience with publicly- and privately-held biotechnology companies. Weaver will report directly to Carlos Buesa, President and Chief Executive Officer of Oryzon, and will be based at Oryzon's U.S. headquarters, located at 245 First Street in Cambridge, MA.
ATOS: 1.67 (+0.11), CLSN: 2.41 (+0.09), EGLT: 10.60 (+0.58), FCSC: 4.75 (+0.50)
Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718
Business Wire - Tue Feb 25, 6:01AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. The previous and future developmental, regulatory and commercial royalty milestones and payments associated with the development and potential future sales of VS-4718 due to Poniard Pharmaceuticals are now owned by Verastem. Verastem retains a license to VS-4718 from The Scripps Research Institute.
VSTM: 7.93 (-0.44), COL: 88.81 (+0.24)